• With recreational legalization on the ballot in Ohio’s general election in November 2023, this proposed transaction will position Vext with a meaningful footprint in the state and the scaled retail presence necessary to generate sustainable long-term returns as the market matures.
• Pro Forma for this announcement and the previously announced Appalachian Pharm acquisition, Vext will have an operating Tier I cultivation facility, an operating manufacturing facility, and four retail dispensaries in Ohio.
• Vext will raise $10 million via a private placement of common shares, the majority of which is expected to be conducted with an existing institutional shareholder, senior management and members of the Company’s board of directors.

Vancouver, British Columbia–(Newsfile Corp. – October 2, 2023) – Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF) (“Vext” or the “Company“), a U.S.-based cannabis operator with vertical operations in Arizona and Ohio¹, is pleased to announce the execution of a letter of intent (the “LOI”) with the members (the “Sellers”) of Big Perm’s Dispensary Ohio, LLC (“Big Perm”) to acquire two cannabis dispensaries located in Ohio (the “Dispensaries”) owned by Big Perm, as well as all licenses and assets related to the business of the Dispensaries (the “Acquired Assets”), for aggregate consideration of approximately $9.8 million, subject to adjustment in certain circumstances (the “Ohio Expansion Transaction”).

The Company also announced a non-brokered private placement of common shares of the Company (“Common Shares“) to raise up to $10 million (the “Offering“). Vext anticipates that one institutional shareholder, as well as certain members of the Company’s senior management team and board of directors will participate for over 60% of the Offering. Unless otherwise noted, all currency references used in this news release are in U.S. currency.

Management Commentary

Eric Offenberger, CEO of Vext, commented, “The addition of two dispensaries to our growing vertical footprint in Ohio represents a critical step toward achieving scale and ensuring long-term returns on capital in this attractive growth market. The overall market environment, particularly from an equity perspective, remains challenging, but now is the right time for Vext to build a platform that will generate growing profitability and cash flow. We appreciate the support of our long-term shareholder base and insiders who have stepped up to support what I am confident will lead to significant value creation.”

Mr. Offenberger continued, “Vext has a proven track record of operating profitably in the limited-license Arizona market and we were early to understand that fully integrated operations and matching long-term cultivation with owned retail demand, is the route to capturing sustained margins and value. Upon closing this transaction, along with the previously announced Appalachian Pharm acquisition, Vext will be positioned for success in the limited license Ohio market through four strategically located dispensaries, bringing us closer to the state cap of five locations.”

Terms of the Ohio Expansion Transaction

Under the terms of the LOI, in consideration for the Acquired Assets, Vext is anticipated to pay cash consideration equal to $9.8 million, subject to adjustments in certain circumstances.

In addition, Vext has agreed to fund approximately $3.4 million of construction costs related to the Dispensaries, which are payable upon closing of the Ohio Expansion Transaction.

The Ohio Expansion Transaction remains subject to a number of customary conditions, including, without limitation: the satisfactory completion of due diligence, the receipt of any required regulatory and third-party approvals, as well as the negotiation of definitive transaction documents. There can be no guarantees that the Ohio Expansion Transaction will be completed as contemplated or at all.

The Company is at arm’s length from Big Perm and each of the Sellers. The Company currently expects that definitive agreement with respect to the Ohio Expansion Transaction will be executed prior to the end of October 2023 and that closing of the Ohio Expansion Transaction will occur in 2024.

About the Ohio Market

The Ohio medical cannabis market continues to grow with a 15% increase in number of patients and 82% increase in number of operating dispensaries over the past 12 months.²

Concurrent Private Placement

Pursuant to the Offering, the Company will offer up to 58,823,529 Common Shares at a price of $0.17 per Common Share (the “Offering Price“) for aggregate gross proceeds of up to $10 million. The Offering is subject to an over-allotment option, allowing the Company to increase the number of Common Shares sold by up to 8,823,529 additional Common Shares for additional proceeds of up to $1.5 million (the “Over-Allotment Option“). The Company may pay finders’ fees to eligible arm’s length third-parties in connection with the Over-Allotment Option.

Proceeds from the Offering, including the Over-Allotment Option (if any), are expected to be used to fund part of the purchase price for the Ohio Expansion Transaction and certain other obligations of the Company in connection with the Ohio Expansion Transaction. Closing of the Offering is expected to occur as soon as practicable, subject to certain customary conditions precedent.

The securities issued pursuant to the Offering, including the Over-Allotment Option (if any), will be subject to resale restrictions, including a hold period of four months and one day pursuant to applicable Canadian securities laws and further restrictions which will be set forth in the Shareholders Agreement (as defined below).

In connection with the Offering, the Company intends to enter into a shareholders agreement (the “Shareholders Agreement“) with certain management shareholders and other subscribers under the Offering (collectively, the “Subject Shareholders“), pursuant to which the Company and the Subject Shareholders will agree to a number of rights and restrictions applicable to the Company and the Subject Shareholders, including, without limitation, the following: (i) an agreement to vote their shares of Vext in favour of the election of the Chief Executive Officer of the Company and a nominee (the “SSOFL Nominee“) of Sopica Special Opportunities Fund Limited (“SSOFL“) to the board of directors of the Company; (ii) the grant of a right of refusal to the other Subject Shareholders for the transfer of any shares of Vext held by the Subject Shareholders; (iii) an agreement, in certain circumstances, to vote their shares of Vext in favour of any sale of the Company proposed by SSOFL and (iv) certain matters which must be approved by the board of directors of the Company (including the SSOFL Nominee), including, without limitation, (a) a liquidation of the Company; (b) the issuance of additional securities of the Company; (c) the incurrence of certain additional debt; (d) certain related party transactions; and (e) amendments to executive compensation arrangements. In connection with the Shareholders Agreement, the Company expects that the SSOFL Nominee will be appointed to the board of directors of the Company on, or as soon as practicable after, closing of the Offering. The Shareholders Agreement, when signed, will constitute applicable shareholder approval, in respect of the Offering and the Shareholders Agreement, for the purposes of the requirements of the Canadian Securities Exchange, as the Subject Shareholders hold greater than 50% of the outstanding votes associated with shares of the Company.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described in this news release in the United States or any other jurisdiction in which such offer, solicitation or sale would be unlawful. Such securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“), or any state securities laws, and, accordingly, may not be offered or sold in the United States or to, or for the account or benefit of, “U.S. persons” (as those terms are defined in Regulation S under the U.S. Securities Act) absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws.

Certain insiders of the Company, including SSOFL (collectively, the “Offering Insiders“), are expected to acquire securities under the Offering. Each of the Offering Insiders may be considered a “related party” as such term is defined in Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101“). Accordingly, the Offering may be a “related party transaction” as defined in MI 61-101. The Company anticipates relying on the exemption from the formal valuation requirement at Section 5.5(a) of MI 61-101 and the exemption from minority approval requirement at Section 5.7(1)(a) of MI 61-101, in respect of participation by the Offering Insiders in the Offering, as neither the fair market value of the securities to be acquired by the Offering Insiders nor the consideration for such securities is anticipated to exceed 25% of the Company’s market capitalization.

Update on APP Acquisition

As previously announced, the Company has received the approval of the Ohio Department of Commerce for the ownership transfer of Appalachian Pharm Processing, LLC, an Ohio limited liability company, together with its subsidiaries and affiliated companies (collectively, “APP“), for a total consideration of approximately $12.5 million, with $11 million paid in cash or promissory notes and $1.5 million through the issuance of Common Shares (the “APP Acquisition“). The Company is working with APP to satisfy the remaining conditions of closing and currently expects that closing of the Ohio Acquisition will occur imminently, subject to the terms of the definitive purchase agreements. For further details about the terms of the APP Acquisition, see the Company’s news releases dated December 15, 2022, and August 23, 2023. As a result of closing of the Ohio Acquisition, Vext will also obtain the right to acquire ownership of a cannabis dispensary in Columbus, Ohio. The Company has applied to the Ohio Board of Pharmacy for an ownership transfer of such dispensary and expects to receive approval this year and to close promptly after receipt of regulatory approval.

Advisors

Eight Capital acted as financial advisor, McMillan LLP and Bianchi & Brandt acted as legal counsel and LodeRock Advisors provided capital markets communication services to Vext.

About Vext Science, Inc.

Vext Science, Inc. is a U.S.-based cannabis operator with vertical operations in Arizona and Ohio. Vext’s expertise spans from cultivation through to retail operations in its key markets. Based out of Arizona, Vext owns and operates state-of-the-art cultivation facilities, fully built-out manufacturing facilities as well as dispensaries in both Arizona and Ohio. The Company manufactures Vapen, one of the leading THC concentrates, edibles, and distillate cartridge brands in Arizona. Its selection of award-winning products are created with Vext’s in-house, high-quality flower and distributed across Arizona and Ohio, as well as through Vext’s partnerships in other states. Vext’s leadership team brings a proven track record of building and operating profitable multi-state operations, with the Company having operated profitably since 2016. The Company’s primary focus is to continue growing in its core states of Arizona and Ohio, bringing together cutting-edge science, manufacturing, and marketing to provide a reliable and valuable customer experience while generating shareholder value.

Vext Science, Inc. is listed on the Canadian Securities Exchange under the symbol VEXT and trades on the OTCQX market under the symbol VEXTF. Learn more at www.vextscience.com and connect with Vext on Twitter/X and LinkedIn.

For more details on the Vapen brand:
Vapen website: VapenBrands.com
Instagram: @vapen
Facebook: @vapenbrands

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Vext’s periodic filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements related to the Offering including the timing and completion thereof, the exercise of the Over-Allotment Option, the use of proceeds of the Offering, Offering Insider participation in the Offering, statements related to the Shareholders Agreement, including the receipt of applicable shareholder approval, statements regarding the Ohio Expansion Transaction, including negotiation and execution of the definitive transaction agreements, the anticipated closing date and receipt of regulatory approvals related thereto, and other statements regarding future developments and the business and operations of the Vext, market projections of the cannabis industry in Ohio, and the Company’s business plans in Ohio, all of which are subject to the risk factors contained in Vext’s continuous disclosure filed on SEDAR+ at www.sedarplus.ca.

Although Vext has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; being engaged in activities currently considered illegal under U.S. Federal laws; change in laws; reliance on management; requirements for additional financing; competition; hindered market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. Because of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Vext disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Vext does not assume any liability for disclosure relating to any other company mentioned herein.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Eric Offenberger
Chief Executive Officer
844-211-3725

For further information:
Jonathan Ross, Vext Investor Relations
jon.ross@loderockadvisors.com
416-244-9851

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OR TO A U.S. PERSON, OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

SOURCE: Vext Science, Inc

¹ Vext has entered into a definitive agreement to acquire Appalachian Pharm Processing, LLC, an Ohio limited liability company, together with its subsidiaries and affiliated companies. Subject to the terms of the definitive purchase agreements, this proposed acquisition (the “APP Acquisition”) is expected to close imminently.

² Ohio Medical Marijuana Control Program.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Company announces agreement that will expand its national chain of health clinics into central Ohio

LOS ANGELES, Sept. 06, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced today that it has entered into a binding to agreement to acquire all of the membership interests in Happier You, LLC, which operates a ketamine clinic in central Ohio. This clinic will be added to Irwin Naturals Emergence, a fast-growing national chain of psychedelic mental-health clinics that has previously acquired 10 different clinics across a total of five states.

Klee Irwin, CEO of Irwin Naturals, said, “We are a first mover in this rapidly expanding sector of mental healthcare. By finding independent, financially sound clinics with exceptional customer care, we’re building a national chain that delivers on the quality of care that is embodied by the Irwin Naturals brand.”

Tara J. Dillon, founder of Happier You, said, “We built our practice out of the belief that it was not just possible, but necessary to ease the suffering of those people who had not been helped by traditional mental-health treatments. Becoming part of Irwin Naturals Emergence allows us to be part of a chain capable of making life-changing impact on a national scale.”

Happier You opened in 2020, founded by Tara Dillon, a registered nurse and family nurse practitioner. The clinic provides IV ketamine-infusion therapy, which is used to treat depression, anxiety as well as bipolar disorder, post-traumatic stress disorder (PTSD) and obsessive-compulsive disorder (OCD).

Irwin Naturals was founded in 1994, and has built itself into a brand recognized in 80 percent of American households¹ with its best-in-class nutraceuticals, such as its famous “Power to Sleep PM.” Irwin Naturals products are stocked on the shelves of more than 100,000 storefronts in North America, and now that brand is moving to the forefront of this new frontier of healthcare.

Klee Irwin, CEO of Irwin Naturals, said, “We’ve earned customer trust through nearly 30 years of caring for their health needs. That makes us a familiar friend, providing assurance to consumers in this new area of care. Just being in this space speaks for both the safety and efficacy of this care.”

Irwin Naturals Emergence already includes clinics in Florida, Vermont, New Hampshire, Iowa and Georgia. By building this national chain of clinics, Irwin Naturals Emergence will drive down operating costs by incorporating its corporate best practices and the savings that come from the ability to buy in larger quantities. These savings can be passed on to consumers, and most importantly, broaden access for those in need through sliding-scale discounts or even pro bono treatment. This will enable the company to serve as a bridge as insurance plans catch up to the importance and power of these treatments.

Currently, ketamine is the only psychedelic available for use in the United States outside of clinical trials. However, MDMA and psilocybin may be authorized for therapeutic use in the future. The effectiveness of these treatments in clinical trials points to the possibility of further revolutionizing the field mental-health treatment. It is estimated that one in four Americans have what would be considered a diagnosable mental-health condition.

Transaction terms

The Agreement is subject to certain customary closing conditions and regulatory approvals. The total consideration is to be paid in a combination of cash and stock, with maximum payable contingent on a number of milestones related to profitability and operation goals. Further detail will be provided upon closing.

About Irwin Naturals

Irwin Naturals has been a household name and best-in-class herbal supplement formulator since 1994. It is now leveraging its brand to enter into both the cannabis and psychedelic industries. On a mission to heal the world with plant medicine, Irwin has operated profitably for over 27 years². Irwin’s growing portfolio of products is available in more than 100,000 retail doors across North America, where nearly 100 million people know the Irwin Naturals brand.³ In 2018, the Company first leveraged its brand to expand into the cannabis industry by launching hemp-based CBD products into the mass market. The Company is now leveraging its famous halo of brand trust with an objective to become one of the first household name brands to offer THC-based products and psychedelic mental health treatment. Irwin Naturals became a publicly traded company on the Canadian Securities Exchange (CSE) in August 2021. The Company’s shares began to be traded on the OTCQB Venture Market in November 2021. More information on the Company’s stock can be found via Bloomberg as well as the Wall Street Journal.

For investor-related information about the Company, please visit ir.irwinnaturals.com/

To contact the Company’s Investor Relations department, please call toll-free at (800) 883-4851 or send an email to [email protected].

“Klee Irwin”
________________________________
Klee Irwin
Chief Executive Officer
T: 310-306-3636
[email protected]

IR Information

Press Contact

Irwin Naturals Investor Relations
Cassandra Bassanetti-Drumm
T: 310-306-3636
[email protected]

Regulatory Overview

The following is a brief summary of regulatory matters concerning ketamine in the United States (“US”). Under the Controlled Substances Act (21 U.S.C. § 811) (the “CSA”), ketamine is currently a Schedule III drug as well as being listed under the associated Narcotic Control Regulations and psilocybin is currently a Schedule I drug. Most US States have enacted Controlled Substances Acts (“State CSAs”) which regulate the possession, use, sale, distribution, and manufacture of specified drugs or categories of drugs and establish penalties for State CSA violations and form the basis for many state and local drug laws enforcement activity. State CSAs have either adopted drug schedules identical or similar to the federal CSA schedules or, in some instances, have incorporated the federal scheduling mechanism. Among other requirements, some US States have established a prescription drug monitoring or review programs collect information about prescription and dispensing of controlled substances for the purposes of monitoring, analysis and education.

In the United States, facilities holding or administering controlled substances must be registered with the US Drug Enforcement Agency (“DEA”) to perform this activity. As such, medical professionals and/or the clinics in which they operate, as applicable, are also required to have a DEA license to obtain and administer ketamine (a “DEA License”). While ketamine is a controlled substance in the United States, it is approved for general anesthetic induction under the US Food, Drug, and Cosmetic Act. Once a drug is approved for use, physicians may prescribe that drug for uses that are not described in the product’s labeling or that differ from those tested by the manufacturer and approved by the Food and Drug Administration (the “FDA”). Licensed medical practitioners may prescribe ketamine legally in Canada or the United States where they believe it will be an effective treatment in their professional judgment.

Please see Irwin’s filing statement on its SEDAR profile for more information on the regulatory environment and regulations surrounding the US THC industry.

Forward-Looking Information

This news release contains certain forward-looking statements that reflect the current views and/or expectations of management of the Company with respect to performance, business and future events. Forward-looking statements can often be identified by words such as “may”, “will”, “would”, “could”, “should”, “believes”, “estimates”, “projects”, “potential”, “expects”, “plans”, “intends”, “anticipates”, “targeted”, “continues”, “forecasts”, “designed”, “goal”, “objective,” or the negative of those words or other similar or comparable words. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business and the industry and markets in which the Company operates. Forward-looking statements in this news release include statements related to information concerning the ability of the Company to perform the terms of the transaction referenced herein; the receipt of all necessary approvals, including regulatory approvals; expectations for other economic, market, business and competitive factors; and the Company actually entering into and doing business in the U.S. cannabis and psychedelics markets. The potential entrance by the Company into these new business segments are in their preliminary stages and may be subject to approval from the board of directors of the Company as well as any regulatory approval, including that of the Canadian Securities Exchange. These statements are based on numerous assumptions that are believed by management to be reasonable in the circumstances, and are subject to a number of risks and uncertainties, including without limitation: board and regulatory approval, including the approval of the Canadian Securities Exchange; Irwin being able to acquire and/or enter into business relationships to enter into these new markets; the Company obtaining the required licenses; and changes to regulations and laws regarding cannabis or psychedelics. Further information on the regulatory environment and risks will be contained in future disclosures. Forward-looking statements are subject to a number of known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from that which are expressed or implied by such forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties, and assumptions which are difficult to predict. Accordingly, readers should not place undue reliance on forward-looking statements and information, which are qualified in their entirety by this cautionary statement. The Company does not undertake any obligation to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law.

Neither the CSE nor its Market Regulator (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Irwin Naturals Inc.

¹ Consumer brand recognition information is based on a formal Company survey with a sample size of 500 randomly selected adults.
² Under several corporate structures, Klee Irwin has operated the Irwin brand profitably since 1994, as measured by EBITDA adjusted for extraordinary costs.
³ Consumer brand recognition information is based on a formal Company survey with a sample size of 500 randomly selected adults.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

TILT connects subsidiaries Jupiter Research and Standard Farms to launch Timeless Vape Brand and Product offerings to the OH market; available today, June 13^th, at select dispensary partners’ launch locations across the state

PHOENIX, June 13, 2022 (GLOBE NEWSWIRE) — TILT Holdings Inc. (“TILT” or the “Company”) (NEO: TILT) (OTCQX: TLLTF), a global provider of cannabis business solutions that include inhalation technologies, cultivation, manufacturing, processing, brand development and retail, today announced that Timeless Refinery (“Timeless”) vaporization products are now available to medical patients in Ohio through a previously announced exclusive partnership.

Timeless is a longstanding client of TILT’s subsidiary, Jupiter Research, LLC (“Jupiter”) and a national cannabis lifestyle house of brands with products available in Arizona, Oklahoma, Missouri, California and now, Ohio through TILT’s subsidiary, Standard Farms LLC (“Standard Farms”). Timeless Vapes provide consumers with a convenient and engaging way to medicate and are now available to Ohio medical patients in the following choices: Energy for an uplifting experience, Chill for balance, and Rest for sleepy relaxation.

“I could not be prouder of our team’s ability to quickly activate our brand partners in new markets. In less than 90 days, and after thoughtful collaboration between the TILT, Standard Farms, Jupiter and Timeless teams, we are excited to launch three premium vape products along with Timeless’ unique flip case and battery hardware in Ohio,” said Gary Santo, CEO of TILT. “We hold a longstanding relationship with Timeless through our Jupiter business and look forward to again leveraging the best of TILT to bring an established West Coast brand to the East.”

“Timeless Vapes is excited to be coming east with a great partner in TILT to provide clean and effective cannabis medicine with innovative engagement to consumers through our pillars of community, culture, and legacy across the country, and we are thrilled to welcome Ohio patients into our community,” said Rocky Huang, founder of Timeless. “The Timeless, Jupiter and Standard Farms teams share a passion for research and development and consumer engagement. We believe this is reflected in the custom Ohio flip case, unique moods, and exciting flavor profiles we are bringing to market.”

Ohio patients can initially find the Timeless Vapes and flip case and battery combos at the following launch partner dispensaries: Rise, G-Leaf, Sunnyside, ZenLeaf, Herbology, Verdant, Bloom, Verilife, Strawberry Fields, and FRX. Dispensaries will be added to the Timeless website as they come online. Timeless will also be hosting on-site activations throughout the state with “Kindness Team” members sharing product education and promotions, including the availability of the “Welcome to Ohio Flip Case.” This starts Wednesday, June 14, at Rise in Cleveland (10:00a.m.-2:00p.m.), Rise Lakewood Detroit (3:00p.m. -5:00p.m.) and Rise Lakewood Madison (3:00p.m.- 5:00p.m.). Patients should call ahead to ensure launch timing and availability in their dispensary. More details on future activations can be found here: Ohio — Timeless Deals (timelesshob.deals)

About TILT
TILT helps cannabis businesses build brands. Through a portfolio of companies providing technology, hardware, cultivation and production, TILT services brands and cannabis retailers across 37 states in the U.S., as well as Canada, Israel, South America and the European Union. TILT’s core businesses include Jupiter Research LLC, a wholly-owned subsidiary and leader in the vaporization segment focused on hardware design, research, development and manufacturing; and cannabis operations, Commonwealth Alternative Care, Inc. in Massachusetts, Standard Farms LLC in Pennsylvania, Standard Farms Ohio, LLC in Ohio, and its partnership with the Shinnecock Indian Nation in New York. TILT is headquartered in Phoenix, Arizona. For more information, visit www.tiltholdings.com.

Instagram: @tiltholdings
Twitter: @TILT_Holdings

About Timeless
Timeless was founded in 2011 with the vision of creating a leading lifestyle brand around high-quality cannabis products and unique engagement through our pillars of “Community, Culture, and Legacy.” Their passion for innovation, unique brand building, and customer engagement has led Timeless to be a leading national House of Brands in the industry. Today, Timeless operates in Arizona, California, Oklahoma, Ohio, and Missouri and is headquartered in Scottsdale, Arizona.

Forward-Looking Information
This news release contains forward-looking information based on current expectations. Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward looking information may include, without limitation, the expected performance of the collaboration between TILT, Jupiter, Standard Farms and Timeless, anticipated development of future product offerings, the opinions or beliefs of management, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies, and outlook of TILT, and includes statements about, among other things, future developments, the future operations, strengths and strategy of TILT. Generally, forward looking information can be identified by the use of forward looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. These statements should not be read as guarantees of future performance or results. These statements are based upon certain material factors, assumptions and analyses that were applied in drawing a conclusion or making a forecast or projection, including TILT’s experience and perceptions of historical trends, the ability of TILT to maximize shareholder value, current conditions and expected future developments, as well as other factors that are believed to be reasonable in the circumstances.

Although such statements are based on management’s reasonable assumptions at the date such statements are made, there can be no assurance that it will be completed on the terms described above and that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information. Accordingly, readers should not place undue reliance on the forward-looking information. TILT assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.

By its nature, forward-looking information is subject to risks and uncertainties, and there are a variety of material factors, many of which are beyond the control of TILT, and that may cause actual outcomes to differ materially from those discussed in the forward-looking statements.

For additional information regarding forward-looking statements and their related risks, please refer to the “Risk Factors and Uncertainties” section in the Annual Information Form of the Company for the year ended on December 31, 2021, which is available on the Company’s SEDAR profile at www.sedar.com.

Company Contact:
Lynn Ricci, VP of Investor Relations & Corporate Communications
TILT Holdings Inc.
[email protected]

Investor Relations Contact:
Sean Mansouri, CFA
Elevate IR
[email protected]
720.330.2829

Media Contact
Juliet Fairbrother
MATTIO Communications
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Body and Mind Flower and Extracts in Arkansas
Expanded Product portfolio in Ohio

LAS VEGAS and VANCOUVER, BC, June 8, 2022 /CNW/ – Body and Mind Inc. (CSE: BAMM) (OTCQB: BMMJ) (the “Company” or “BaM“), a multi-state US cannabis operator, is pleased to provide an update on growth of wholesale operations.

Ohio

Ohio manufacturing operations continue to expand with extracted product offerings including Body and Mind branded shatter, crumble, ambrosia and kief available at the Body and Mind Cleveland dispensary and in more than 10 other dispensaries across Ohio. The Company has recently received final approval for kitchen operations and anticipates bringing popular Nevada edible products including Pretzel Bites, Krispy Bites and Chocolate Bites to

the Ohio market in the near term.

Arkansas

The Company has completed phenotyping of the new strains at the Arkansas cultivation, which have received excellent feedback in the market. As cultivation operations have ramped, the Company has been selling flower through the Body and Mind dispensary in West Memphis, Arkansas. The cultivation team has achieved a steady state of cultivation operations and wholesale of Body and Mind branded flower has commenced through numerous other dispensaries in Arkansas. The proprietary strains include G-Baby 99, Puppy Breath, Chem Dela Cake and Sundae Pie, all featuring strong terpene profiles. Body and Mind has also collaborated with renowned Arkansas extractors Dark Horse and Bold to offer Body and Mind branded shatter and crumble, which is available at the Body and Mind dispensary and other dispensaries in Arkansas. The Body and Mind dispensary has been offering home delivery in Arkansas and continues to see deliveries expanding.

California

Body and Mind has collaborated with Froot to create custom Body and Mind products including Body and Mind pre-rolls which are now available at all Body and Mind dispensaries in California. The Body and Mind pre-rolls feature quality flower in a custom branded BaM logoed 1 gram pre-rolled joint. The Company will continue to review collaboration opportunities while the planned manufacturing operation moving through final local approvals.

“We are excited to continue expanding our proven Nevada products into the limited license states of Ohio and Arkansas“, stated Michael Mills, CEO of Body and Mind. “Our team continues to produce sought after flower, extracts and edibles as we bring our deep experience and proven product portfolio from the Nevada market to our growing operations.”

Q3 Periodic Report and Earnings Update

The Company anticipates filing its Form 10-Q for the three and nine months ended April 30, 2022 on June 20, 2022 with a Q3 earnings call scheduled for 5:00 PM Eastern on June 21, 2022.

Conference Call Details

Confirmation #: 30671046

Local: Toronto: 416-764-8659
North American Toll Free: 1-888-664-6392

Encore Replay

Encore Replay Local: (+1) 416 764 8677
Encore Replay North American Toll Free: (+1) 888 390 0541
Encore Replay Entry Code: 671046 #
Encore Replay Expiration Date: 06/28/2022

About Body and Mind Inc.

BaM is an operations focused US multi-state cannabis operator investing in high quality medical and recreational cannabis cultivation, production and retail.

BaM continues to expand operations in Nevada, California, Arkansas, Ohio and Michigan and is dedicated to increasing shareholder value by focusing time and resources on improving operational efficiencies, facility expansions, state licensing opportunities as well as mergers and acquisitions.

Our wholly owned Nevada subsidiary was awarded one of the first medical marijuana cultivation licenses and holds cultivation and production licenses. BaM products include dried flower, edibles, oils and extracts as well as GPEN Gio cartridges. BaM cannabis strains have won numerous awards including the 2019 Las Vegas Weekly Bud Bracket, Las Vegas Hempfest Cup 2016, High Times Top Ten, the NorCal Secret Cup and the Emerald Cup.

Please visit www.bodyandmind.com for more information.

Instagram:@bodyandmindBaM
Twitter: @bodyandmindBaM

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Safe Harbor Statement

Except for the statements of historical fact contained herein, the information presented in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. Any other statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects” or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans, “estimates” or “intends”, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and should be viewed as “forward-looking statements”. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such risks and other factors include, among others, the actual results of activities, variations in the underlying assumptions associated with the estimation of activities, the availability of capital to fund programs and the resulting dilution caused by the raising of capital through the sale of shares, accidents, labor disputes and other risks. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release and in any document referred to in this news release.

Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the Securities and Exchange Commission. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities.

SOURCE Body and Mind Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

LOS ANGELES, May 24, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced today it has licensed its brand to BeneLeaves Ltd, an Ohio manufacturer of cannabis products. BeneLeaves will produce and distribute formulas such as Irwin Naturals’ Power to Sleep with THC.

Irwin’s CEO, Klee Irwin, said, “It is clear that the value of our highly trusted brand, known by over 100 million people**, is recognized by operators in the cannabis industry. With this agreement, the third in one month, we will now have our THC augmented products in states with 2021 cannabis sales of around $8.7 billion¹. We are excited about our entry into Ohio, and look forward to working with the team at BeneLeaves, one of the largest in-state manufacturers and distributors with a reputation for quality of product and service, as well as a strong focus on driving rapid growth.”

Bill Williams Jr., President and CEO of BeneLeaves, commented, “Adding the Irwin Naturals brand to our portfolio is a game-changer for us and the Ohio market. To have a brand that is trusted by millions entering the sector is a validation of the mainstreaming of medical cannabis, and will help further erode mental barriers to adoption of this amazing plant. We are proud to have been selected as the Irwin Natural partner to bring these amazing products to the people of Ohio.”

About Irwin Naturals

Irwin Naturals has been a household name and best-in-class nutraceutical company since 1994. It is now leveraging its brand into both the cannabis and psychedelic sectors. On a mission to heal the world with plant medicine, Irwin has operated profitably for over 27 years*. The growing portfolio of products is available in more than 100,000 retail doors across North America, where 80% of households know the Irwin Naturals brand**. In 2018, the Company first leveraged its brand to expand into the cannabis industry by launching hemp-based CBD products into the mass market. The Company is now leveraging its famous halo of brand trust to become, perhaps, the first household name brand to offer THC-based products. Its rapidly growing national chain of psychedelic mental health clinics is called Irwin Naturals Emergence.

*Under several corporate structures, Klee Irwin has operated the Irwin brand profitably since 1994, as measured by EBITDA adjusted for extraordinary costs.

**Based on a formal Company survey with a sample size of 500 randomly selected adults.

For investor-related information about the Company, please visit ir.irwinnaturals.com/

To contact the Company’s Investor Relations department, please call toll-free at (800) 883-4851 or send an email to [email protected].

“Klee Irwin”
________________________________
Klee Irwin
Chief Executive Officer
T: 310-306-3636
[email protected]

Forward-Looking Information

This news release contains certain forward-looking statements that reflect the current views and/or expectations of management of the Company with respect to performance, business and future events. Forward-looking statements can often be identified by words such as “may”, “will”, “would”, “could”, “should”, “believes”, “estimates”, “projects”, “potential”, “expects”, “plans”, “intends”, “anticipates”, “targeted”, “continues”, “forecasts”, “designed”, “goal”, or the negative of those words or other similar or comparable words. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business and the industry and markets in which the Company operates. The Company does not undertake any obligation to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law.

Neither the CSE nor its Market Regulator (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Irwin Naturals Inc.

¹ Sources: https://cannabusinessplans.com/california-cannabis-market/#:~:text=In%202021%2C%20California%20retail%20stores%20sold%20over%20%245.2,five%20states%20represented%2050%20percent%20of%20U.S.%20sales.
Source: https://mjbizdaily.com/colorados-2021-cannabis-sales-set-another-annual-record-at-2-22-billion/

Oklahoma Medical Cannabis Sales on Pace to Hit $1 Billion in 2021

https://www.crainscleveland.com/jeremy-nobile-blog/ohio-topped-381-million-marijuana-sales-2021#:~:text=Ohio%20reported%20at%20least%20%24381%20million%20in%20medical,the%20full%20story%20and%20other%20breaking%20news%20today.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

<!– (adsbygoogle = window.adsbygoogle || []).push({ google_ad_client: “ca-pub-5707738102681835”, enable_page_level_ads: true }); –>

<!– Click –>

1906, a cannabis product innovator, is the creator of highly functional formulations that combine moderately-dosed cannabis with targeted plant medicines

TILT to launch 1906 Drops in Pennsylvania and Ohio, as well as the 1906 line of chocolates in the Massachusetts market

PHOENIX, Aug. 12, 2021 (GLOBE NEWSWIRE) — TILT Holdings Inc. (“TILT or the “Company”) (CSE: TILT) (OTCQX: TLLTF), a global provider of business solutions to the cannabis industry that includes inhalation technologies, cultivation, manufacturing, processing, brand development and retail, announced a multi-state licensing agreement with cannabis product innovator brand 1906 (“1906”).

Through its subsidiaries Standard Farms, LLC in Pennsylvania, Standard Farms Ohio, LLC and Commonwealth Alternative Care, Inc. (“CAC”) in Massachusetts, TILT will provide full-service wholesale manufacturing, packaging and distribution services to accelerate the availability of 1906’s portable, non-smokable cannabis products to patients in the rapidly-growing adult-use and medical markets that TILT serves.

Since coming to market in Colorado in 2016, 1906 has been one of the fastest growing brands in the U.S. Pending regulatory approval, later this year TILT expects to launch 1906’s zero-calorie, allergen-free pills (“Drops”) in Pennsylvania and Ohio, as well as 1906’s line of premium chocolates in Massachusetts, where their Drops are currently available to both medical patients and adult-use consumers. 1906 products are designed to deliver six unique experiences including*:

• Go – A special blend of plant medicines, caffeine, and cannabis promoting alertness, energy, and focus. Each Go Drop contains 5mg THC and 5mg CBD.
• Genius – An optimal blend of five plant medicines, caffeine, and cannabis promoting cognitive performance. Each Genius Drop contains 2.5mg THC and 2.5mg CBD.
• Bliss – A stimulating blend of euphoria-inducing plant medicines and cannabis promoting a bubbly sense of well-being and extroverted happiness. Each Bliss Drop contains 5mg THC and 5mg CBD.
• Love – An aphrodisiac made from five exotic herbs renowned for their love-enhancing properties, plus cannabis to increase sensuality. ​​Each Love Drop contains 2.5mg THC and 2.5mg CBD.
• Chill – A perfectly balanced blend of stress-reducing plant medicines and relaxing cannabis promoting a tranquil mind and a calm body. Each Chill Drop contains 5mg THC and 25mg CBD.
• Midnight – A highly targeted blend of sleep-inducing plant medicines and relaxing cannabis promoting deeper and more restful nights. Each Midnight Drop contains 5mg THC and 5mg CBD.

“Since announcing our brand partnership strategy earlier this year, we continue to attract some of the most exciting and unique brands in the space,” said Gary Santo, CEO of TILT Holdings. “1906 marks another stellar addition to our growing roster of brand partners, and their willingness to enter into multiple markets with us reinforces the value proposition we offer our partners as well as 1906’s faith and trust in TILT’s ability to deliver. Our team continues to perform at a high level, and as we seek to create value for our shareholders, I could not be more proud of our ability to execute.”

“1906 is committed to making cannabis accessible, easy and unintimidating for all users. We’re thrilled to join forces with a partner who has the expertise and operational systems to help us reach more patients as we continue our eastward expansion,” says 1906 Co-founder and CEO Peter Barsoom. “TILT has brought a host of impressive brands to the marketplace—they have what it takes to help us scale production and distribution in key states.”

*Due to differing state regulations, not all products will be immediately available in all markets.

About TILT
TILT helps cannabis businesses build brands. Through a portfolio of companies providing technology, hardware, cultivation and production, TILT services brands and cannabis retailers across 35 states in the U.S., as well as Canada, Israel, Mexico, South America and the European Union. TILT’s core businesses include Jupiter Research, LLC , a wholly owned subsidiary and leader in the vaporization segment focused on hardware design research and manufacturing; and cannabis operations CAC in Massachusetts and Standard Farms, LLC in Pennsylvania. For more information, visit www.tiltholdings.com

About 1906
1906 is a leader in innovative self-care, creating groundbreaking functional formulations combining cannabis and plant medicines, currently available in four states. 1906’s lineup delivers six distinctive experiences that promote sleep, energy, arousal, relaxation, cognitive focus, and a happy mood, all in consistently fast-acting formulations using organically-grown, pesticide-free cannabis. User-friendly, portable and thoughtfully engineered, they deliver curated effects within 20 minutes—faster than any other edible on the market. The rapid-onset formulations help consumers get the most out of their days and nights while staying pleasantly in control. For more information on 1906, please visit www.1906newhighs.com.

Forward-Looking Information
This news release contains forward-looking information based on current expectations. Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward looking information may include, without limitation, Standard Farms, PA, Standard Farms, OH, and CAC’s ability to successfully manufacture and distribute 1906 products in Pennsylvania, Ohio and Massachusetts, the expected launch of new 1906 products, expected attributes of new 1906 products, the success of TILT’s brand strategy, the opinions or beliefs of management, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of TILT, and includes statements about, among other things, future developments, the future operations, strengths and strategy of TILT. Generally, forward looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. These statements should not be read as guarantees of future performance or results. These statements are based upon certain material factors, assumptions and analyses that were applied in drawing a conclusion or making a forecast or projection, including TILT’s experience and perceptions of historical trends, the ability of TILT to maximize shareholder value, current conditions and expected future developments, as well as other factors that are believed to be reasonable in the circumstances.

Although such statements are based on management’s reasonable assumptions at the date such statements are made, there can be no assurance that it will be completed on the terms described above and that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information. Accordingly, readers should not place undue reliance on the forward-looking information. TILT assumes no responsibility to update or revise forward- looking information to reflect new events or circumstances unless required by applicable law.

By its nature, forward-looking information is subject to risks and uncertainties, and there are a variety of material factors, many of which are beyond the control of TILT, and that may cause actual outcomes to differ materially from those discussed in the forward-looking statements.

For additional information regarding forward-looking statements and their related risks, please refer to the “Risk Factors and Uncertainties” section in the Management Discussion and Analysis of the Company for the quarter ended on March 31, 2021, which is available on the Company’s SEDAR profile at www.sedar.com.

The CSE has neither approved nor disapproved the contents of this news release.

Investor Relations Contact:
Taylor Allison
[email protected]

Media Contact:
Juliet Fairbrother
MATTIO Communications
[email protected]
631.338.5343

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

VANCOUVER, BC, July 20, 2021 /CNW/ – Vext Science, Inc. (“Vext” or the “Company”) (CSE: VEXT) (OTCQX: VEXTF) a cannabinoid operator and brand leader based in Arizona, leveraging its core expertise in extraction, manufacturing, cultivation and marketing to build a profitable multi-state footprint, today provided an update on its progress toward establishing a retail presence in the State of Ohio.

As announced on March 15, 2021, Vext has signed a letter of intent (the “LOI”) to form a joint venture to access a provisional cannabis dispensary license (the “Provisional License”) held by an Ohio entity (the “License Co.”). The License Co. has now received a Certificate of Operation by the Ohio Board of Pharmacy (the “Board”) and is fully operational. Once the License Co. has been operational for 12 months, Vext and its joint venture partner may apply to the Board for a change in ownership of the Provisional License.

Ohio’s state-sanctioned cannabis sales are expected to be between US$350 million to US$425 million in 2021, under a highly regulated, medical-only framework, compared to US$221.5 million in 2020¹.

Eric Offenberger, CEO of Vext commented, “As we continue to build out our profitable Arizona footprint, we are looking to Ohio as another leg of growth for Vext. The Vapen brand is already being sold in dispensaries across the State. In 12 months, alongside our joint venture partner, we will be positioned to gain access to a coveted retail license in a premier location. The Ohio medical market is demonstrating solid growth, exceeding initial industry projections. It also displays the characteristics we look at from a return on capital perspective, including a limited license structure very similar to what we are familiar with in Arizona, and the potential to transition to adult-use at some point in the future. Between the expansion of our cultivation footprint in Arizona, which we expect will support continued growth in the state, and our pending build-out in Ohio, the next 12 months will be a very exciting period for Vext.”

For further information regarding the LOI, see the press release filed on Vext’s SEDAR profile on March 15, 2021.

About VEXT Science, Inc.

Vext Science, Inc. is a US-based Cannabis THC and Hemp cannabinoid products company manufacturing THC cartridges, concentrates, edibles and accessories under the Vapen Brand, and Hemp based products under the Pure Touch Botanicals brand as well as the Vapen CBD brand. Based in Arizona, Vext Science, Inc. has one of the leading THC concentrates, edibles, and distillate cartridge brands sold in most of the state’s 100+ dispensaries. Herbal Wellness Center is one of Arizona’s leading dispensaries and we execute all aspects of the cultivation, extraction, edibles infusion and manufacturing processes which insures a product of the highest quality and purity. Product quality and purity are core to our marketing strategy. Vext Science, Inc. is executing its business growth by leveraging experience and expertise in extractions, product manufacturing, and marketing to expand in the U.S. through revenue and profit-sharing joint venture partnerships. For more information visit our website at www.VextScience.com.

For more details on the Vapen brand:
Vapen website: VapenBrands.com 
Instagram: @vapen 
Facebook: @vapenclear

COVID-19 Risk Factor

VEXT may be impacted by business interruptions resulting from pandemics and public health emergencies, including those related to COVID-19. An outbreak of infectious disease, a pandemic, or a similar public health threat, such as the recent outbreak of COVID-19, or a fear of any of the foregoing, could adversely impact VEXT by causing operating, manufacturing, supply chain, and project development delays and disruptions, labor shortages, travel, and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how VEXT may be affected if such a pandemic persists for an extended period of time, including as a result of the waiver of regulatory requirements or the implementation of emergency regulations to which VEXT is subject. Although VEXT has been deemed essential and/or has been permitted to continue operating its facilities in the states in which it operates during the pendency of the COVID-19 pandemic, there is no assurance that the Company’s operations will continue to be deemed essential and/or will continue to be permitted to operate. VEXT may incur expenses or delays relating to such events outside of its control, which could have a material adverse impact on its business, operating results, financial condition and the trading price of the Company’s Common Shares.

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in VEXT’s periodic filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should, on track” and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements related COVID-19, to future developments and the business and operations of VEXT, the anticipated size of the cannabis market in Ohio, the formation of the joint venture pursuant to the LOI and the transfer of the Provisional License, which are subject to the risk factors contained in Vext’s continuous disclosure filed on SEDAR.

Although VEXT has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; being engaged in activities currently considered illegal under U.S. Federal laws; change in laws; reliance on management; requirements for additional financing; competition; hindered market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. Because of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward- looking statements in this news release are made as of the date of this release. VEXT disclaims any intention or obligation to update or revise such information, except as required by applicable law, and VEXT does not assume any liability for disclosure relating to any other company mentioned herein.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Eric Offenberger
Chief Executive Officer
844-211-3725

SOURCE VEXT Science, Inc.

For further information: Jonathan Ross, VEXT Investor Relations, [email protected], 416-283-0178

Related Links

https://vextscience.com/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

California Manufacturing Facility Receives Local Approval

VANCOUVER, BC, June 11, 2021 /CNW/ – Body and Mind Inc. (CSE: BAMM) (OTCQB: BMMJ) (the “Company” or “BaM”), a multi-state operator, is pleased to provide an update on development and license approval of the Ohio production facility and an update on California manufacturing and distribution.

BaM and NMG Ohio, LLC have completed construction of the Ohio production facility and have received a certificate of occupancy and approval from the Department of Commerce to commence processing operations comprising manufacturing of extracted products, oils and edibles. The production facility is located next to the Body and Mind dispensary west of Cleveland and anticipates producing a wide variety of Body and Mind branded offerings for the Ohio market.

“As early dispensary operators in Ohio we’ve had significant feedback from customers and patients around non-flower choices and are looking forward to bringing our award-winning Body and Mind offerings to Ohio,” stated Michael Mills, CEO of Body and Mind.” We have seen interest in the Ohio market growing for non-flower product categories including shatter, badder, oils and edibles and our strategy of licencing a BHO production operation will allow us to produce a wide range of products for the growing Ohio market.”

California Manufacturing Facility

The Company has executed a lease and received local approval for a cannabis manufacturing facility in California. “We have been working with the property owner and local and state representatives for months to advance a wholly-owned manufacturing facility, which will also include a distribution license,” stated Trip Hoffman, COO of Body and Mind. “Our development team has done a fantastic job with the Ohio facility and are looking forward to advancing the California opportunity which is anticipated to be funded from cashflow. Our sales data has outlined the success of our Body and Mind branded products and our focus on revenue growth and increased margins points to the benefit of advancing our own operation. We look forward to moving forward with development of our 100% owned manufacturing and distribution operation.”

The Company has applications in process with the California Bureau of Cannabis Control (BCC) for a type N manufacturing license, and with the California Department of Public Health (CDPH) for a distribution license, which is anticipated to allow the Company to manufacture and distribute its BaM branded flower products, extracts, oils and edibles. In preparation for a change in manufacturing operations, Body and Mind has provided increased inventory to its ShowGrow dispensaries and other California customers, is reviewing bridging manufacturing options, and has terminated prior brand director agreements.

Arkansas Cultivation

Cultivation operations are advancing in West Memphis, Arkansas with Comprehensive Care Group. The cultivation facility has sprouted the initial batches of seeds and have advanced many of the seedlings into soil media to accelerate the vegetative state. The first harvest is estimated to occur in 16 weeks.

FY2021 Q3 Financial Results

The Company anticipates filing its Quarterly Report on Form 10-Q for the nine month period ended April 30, 2021 on or before June 21^st, and details of an earnings call will be disseminated around the same time.

About Body and Mind Inc.

BaM is an operations focused multi-state operator investing in high quality medical and recreational cannabis cultivation, production and retail. Our wholly owned Nevada subsidiary was awarded one of the first medical marijuana cultivation licenses and holds cultivation and production licenses. BaM products include dried flower, edibles, oils and extracts as well as GPEN Gio cartridges. BaM cannabis strains have won numerous awards including the 2019 Las Vegas Weekly Bud Bracket, Las Vegas Hempfest Cup 2016, High Times Top Ten, the NorCal Secret Cup and the Emerald Cup.

BaM continues to expand operations in Nevada, California, Arkansas and Ohio and is dedicated to increasing shareholder value by focusing time and resources on improving operational efficiencies, facility expansions, state licensing opportunities as well as mergers and acquisitions.

Please visit www.bamcannabis.com for more information.
Instagram: @bodyandmindBaM
Twitter: @bodyandmindBaM

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Safe Harbor Statement

Except for the statements of historical fact contained herein, the information presented in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. Any other statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects” or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans, “estimates” or “intends”, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and should be viewed as “forward-looking statements”. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such risks and other factors include, among others, the actual results of activities, variations in the underlying assumptions associated with the estimation of activities, the availability of capital to fund programs and the resulting dilution caused by the raising of capital through the sale of shares, accidents, labor disputes and other risks. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release and in any document referred to in this news release.

Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the Securities and Exchange Commission. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities.

SOURCE Body and Mind Inc.

For further information: Investor Relations, Jonathan Paterson, +1 203 862 0492, [email protected]; Eric Balshin, +1 647 499 3746, [email protected]; Company Contact: Michael Mills, CEO, Tel: 800-361-6312, [email protected]

Related Links

https://bamcannabis.com/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Cannabis Dispensary Franchise Continues Rapid Growth Through Strategic Franchise Partnerships; Partners with Experienced Entrepreneur with Development Underway in Michigan and Ohio

PHOENIX, May 6, 2021 /PRNewswire/ — Item 9 Labs Corp. (OTCQX: INLB), a vertically integrated cannabis company, announced today that its dispensary franchise, Unity Rd., has signed a multi-unit franchise agreement with entrepreneur Kevin Waltermire to open three Unity Rd. shops. Due to the industry’s unique business opportunities, Waltermire is seeking immediate entrance by purchasing an existing dispensary to convert into a Unity Rd. as well as applying for dispensary licenses in Michigan and Ohio. The $INLB and Unity Rd. teams are already working to identify potential acquisition opportunities across the two states as part of its support.

Waltermire is no stranger to the cannabis industry. He experienced the value of Unity Rd. first-hand when he played a critical role in developing the brand and shop design as the Director of Business Development for Unity Rd. from October 2018 to March 2020.

“Regardless of your professional background, opening a dispensary is an incredibly complicated and lengthy process,” explained Waltermire. “The Unity Rd. franchise opportunity is the best way to eliminate a lot of the hurdles and ensure compliance and seamless operations. Their team is going to make it so much easier for myself and many others to enter this fast-growing industry.”

Unity Rd. offers one of the safest routes for entrepreneurs looking to enter an industry that boasts high growth potential, helping franchise partners confidently enter the complex cannabis space. Its veteran team passes on their knowledge and trusted resources, as well as provides the ongoing support needed to compliantly and successfully operate a dispensary. With a collective 120-plus years’ experience in the legal cannabis industry, Unity Rd.’s time-tested Standard Operating Procedures (SOPs) guide franchise partners through every operational function of the business.

“Franchising allows those who may not have the knowledge or access to necessary resources to have a viable opportunity to flourish,” said Unity Rd. Chief Franchise Officer Mike Weinberger. “In my nearly two decades in franchising, I’ve never seen an industry quite like this [cannabis] that could benefit so much from the franchise business model. Beyond helping industry newcomers and existing operators find success, franchising is also helping standardize the cannabis industry.”

Unity Rd. franchise partners now receive even more resources and supply chain connections as the brand was recently acquired by Item 9 Labs Corp., an award-winning cannabis operator.

“Having worked in the industry with product brands and dispensaries, I’m very aware of the supply chain issues many dispensary owners run into – I’ve seen it play out right here in Denver. So, when I heard the news of the acquisition and learned how Item 9 Labs would alleviate those pain points, I was sold,” added Waltermire.

The combination of the Unity Rd. cannabis retail franchise and premium Item 9 Labs products makes Item 9 Labs Corp. one of the first vertically integrated cannabis franchise companies in the country. Known for its extensive catalogue of products, Item 9 Labs currently offers 75 active cannabis strains and 150-plus differentiated cannabis vape products as well as premium concentrates. As Unity Rd. grows its franchise network, Item 9 Labs plans to develop or partner with cultivation facilities in states where Unity Rd. franchise partners open cannabis retail shops. This move will give Unity Rd. operators front-of-the-line access to a reliable product supply chain.

Despite economic challenges brought on by the pandemic, the demand for cannabis products surged to unprecedented levels with nearly every state experiencing record sales throughout 2020. Growth is anticipated to continue in 2021 with a big year for cannabis law reform on both the state and federal levels – opening opportunities for the industry to explode, with industry projections to top $24 billion by year-end.

Currently, Unity Rd. has signed multiple agreements with 14 entrepreneurial groups across the country. The total investment ranges from $1 million to $2.5 million, including a $100,000 franchise fee for a single unit or $250,000 for three units. Parties interested in becoming a Unity Rd. franchise partner should have access to a minimum $1 million in liquid capital. Franchise partners may be owner-operators or passive owners with a designated, experienced manager running operations.

To learn more about Unity Rd. franchise opportunities, contact [email protected] or 720-923-5262, or visit unityrd.com. For additional information on Item 9 Labs Corp., visit item9labscorp.com.

About Unity Rd.:
Unity Rd. is bridging the two previously disconnected worlds of cannabis and franchising. The industry trailblazer is the first to bring the cannabis dispensary franchise model to the United States—with duality of prowess in both industries to back it up. Built up from a collective 200 years in the legal cannabis industry and franchising, the company helps eager operators enter the complex industry with ease. The marijuana franchise pioneer offers its partners the knowledge, resources, and ongoing support needed to compliantly and successfully operate a dispensary. Launched in 2018, Unity Rd. has signed multiple agreements with more than 10 entrepreneurial groups across the country. Recently, it was named one of the top cannabis retail leaders in the nation by MJBizDaily magazine and one of the “Best Cannabis Companies to Work For” in both the dispensary and cultivation categories in Cannabis Business Times’ elite 2020 list. The company is also the first cannabis business to earn a Franchise Times Dealmakers award. For more information, visit unityrd.com.

About Item 9 Labs Corp.:
Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator and dispensary franchisor, delivering premium products from its large-scale cultivation and production facilities in the United States. The award-winning Item 9 Labs brand specializes in best-in-class products and user experience across several cannabis categories. The company also offers a unique dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. Item 9 Labs brings the best industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation. The veteran management team combines a diverse skill set with deep experience in the cannabis sector, franchising, and the capital markets to lead a new generation of public cannabis companies that provide transparency, consistency, and well-being. Headquartered in Arizona, the company is currently expanding its operations space by 650,000+ square feet on its 50-acre site, one of the largest properties in Arizona zoned to grow and cultivate flower. For additional information, visit item9labscorp.com.

Media Contact:
Liz Robinson, Fishman PR
Phone: 847-945-1300
Email: [email protected]

Investor Contact:
Item 9 Labs Corp.
Phone: 800-403-1140
Email: [email protected]

SOURCE Item 9 Labs Corp.

Related Links

http://item9labscorp.comFran

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.